Search research articles
Contact Us
Filters
Showing results (161-170 of 176) with videos related to
Page
of 18
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 7, 2012
A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer
Lee S Rosen, Herbert I Hurwitz, Michael K Wong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 20, 2007
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy
David B Agus, Christopher J Sweeney, Michael J Morris, et al.
Clinical Genitourinary Cancer
|
December 25, 2013
A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma
David S Hong, Michael S Gordon, Wolfram E Samlowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2010
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules
Ranjana H Advani, Herbert I Hurwitz, Michael S Gordon, et al.
Clinical Imaging
|
March 8, 2011
CT- and computer-based features of small hamartomas
Yao Huang, Dong ming Xu, Artit Jirapatnakul, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2014
An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer
Michael S Gordon, Francisco Robert, Daniela Matei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 2013
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer
Johanna C Bendell, Michael S Gordon, Herbert I Hurwitz, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 12, 2008
Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling
Yi Tang, Krit Kitisin, Wilma Jogunoori, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 14, 2010
Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors
Michael S Gordon, Christopher S Sweeney, David S Mendelson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 4, 2007
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline
D Andrew Loblaw, Katherine S Virgo, Robert Nam, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 176) with videos related to
Sort By:
Page
of 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 7, 2012
A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer
Lee S Rosen, Herbert I Hurwitz, Michael K Wong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 20, 2007
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy
David B Agus, Christopher J Sweeney, Michael J Morris, et al.
Clinical Genitourinary Cancer
|
December 25, 2013
A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma
David S Hong, Michael S Gordon, Wolfram E Samlowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2010
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules
Ranjana H Advani, Herbert I Hurwitz, Michael S Gordon, et al.
Clinical Imaging
|
March 8, 2011
CT- and computer-based features of small hamartomas
Yao Huang, Dong ming Xu, Artit Jirapatnakul, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2014
An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer
Michael S Gordon, Francisco Robert, Daniela Matei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 2013
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer
Johanna C Bendell, Michael S Gordon, Herbert I Hurwitz, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 12, 2008
Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling
Yi Tang, Krit Kitisin, Wilma Jogunoori, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 14, 2010
Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors
Michael S Gordon, Christopher S Sweeney, David S Mendelson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 4, 2007
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline
D Andrew Loblaw, Katherine S Virgo, Robert Nam, et al.
Page
of 18